Hi all, As day 3 of the 65th ASH Annual Meeting and Exposition unfolds, I’m excited to share some key chronic lymphocytic leukemia (CLL) abstracts.…

Hi all, I hope everyone is having a productive time at the 65th ASH Annual Meeting and Exposition! Today, I’d like to share some of…

Hi all, Happy ASH! I’m excited to share some of my favorite chronic lymphocytic leukemia (CLL) abstracts from the first day of the 65th ASH…

Hello everyone, This month, I want to bring your attention to an excellent review article on the cardiovascular toxicities associated with various BTK inhibitors (BTKi).…

Hello Everyone, This month I would like to highlight some pivotal findings from recent CLL research, particularly focusing on patients’ quality of life. The SEQUOIA…

Hey Everyone, I hope you’re all doing well. I wanted to share some exciting findings from recent studies shedding light on venetoclax resistance in CLL.…

Dear Colleagues, I wanted to share some insights regarding the recent publication titled “Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax…

Hey everyone, I wanted to share some important updates regarding the recent changes to the NCCN treatment guidelines. These changes align with the data we’ve…

Hi all, In this month’s email, I want to focus on the evolving role of BTK inhibitors (BTKi) in chronic lymphocytic leukemia (CLL). I included…

  Hi All, This week we saw the publication of a large randomized trial using various venetoclax combinations in front line CLL patients vs chemotherapy…